Key Highlights

• On 4 November 2026, Acadia reported third-quarter DAYBUE net sales of US$140 million, up 39% from US$101 million a year earlier.

• It also raised its 2026 DAYBUE guidance to US$505-520 million from US$480-510 million.

• Acadia's net sales were US$125 million, up from US$101 million in the first quarter of 2026, according to Neuren's August announcements.

• Neuren's own 2026 Royalty guidance, set before the latest Acadia update, was around US$53-56 million.

Why are investors watching Neuren Pharmaceuticals (ASX:NEU) as its first European launch of DAYBUE approaches? Because a royalty stream built on one US drug is about to gain a second major market, just as the company funds its next treatment candidate from its own cash and starts paying dividends.

The central development: a more encouraging royalty base and Europe next

Neuren is a Melbourne-based biotechnology company. It does not sell DAYBUE (trofinetide), the first approved treatment for Rett syndrome, itself. US-based Acadia Pharmaceuticals holds the commercial rights and pays Neuren royalties on sales.

On 4 November 2026, Acadia reported third-quarter DAYBUE net sales of US$140 million, up 39% from US$101 million a year earlier. It also raised its 2026 DAYBUE guidance to US$505-520 million from US$480-510 million. Those are Acadia's figures and guidance, not Neuren's, but they set the pace for Neuren's royalty income.

The second quarter had already been a record. Acadia's net sales were US$125 million, up from US$101 million in the first quarter of 2026, according to Neuren's August announcements. Neuren's own 2026 royalty guidance, set before the latest Acadia update, was around US$53-56 million.

What Neuren does and how it earns

Neuren's income today comes mainly from royalties and, over time, milestone payments. It also earns interest on a large cash balance. Its costs are mostly research and development, plus modest corporate expenses.

Its pipeline is built around neurodevelopmental disorders, where few treatments exist. Beyond DAYBUE, the lead candidate is NNZ-2591 (ercanetide), now in a Phase 3 study in Phelan-McDermid syndrome. The company is also working on Pitt Hopkins syndrome and hypoxic-ischaemic encephalopathy.

Half-year results: higher revenue, lower profit

For the half-year to 30 June 2026, released on 26 August, Neuren reported:

• Revenue of A$42.7 million, up 8% from A$39.7 million.

• Net profit after tax of A$4.9 million, down 68% from A$15.0 million.

• Basic Earnings Per Share of 3.83 cents, against 11.88 cents.

• DAYBUE royalty income of US$23.3 million, up 29% in US dollars.

• Research and Development spending of A$27.4 million, up A$12.5 million.

The profit decline is not a sign of weaker royalties. Spending on the NNZ-2591 Phase 3 trial drove it, and management has said the programme is funded from existing cash. The company also repurchased about A$3.9 million of shares in the period.

A first dividend

Neuren declared its first dividend: 15 cents per share, fully franked, paid on 7 October 2026. Reports of the results presentation say it equals about 90% of the first-half "Available Pool", a measure of royalty and interest income after costs and tax. The stated policy is to distribute 70-100% of that pool.

Dividends under such a policy can move with royalties, exchange rates and research spending. They are not a fixed commitment, and the company's full-year pool estimate was reported at roughly A$48-52 million.

Europe, Japan and the pipeline

The European Commission approval process followed a positive opinion from the European Medicines Agency after re-examination. Neuren has said the first commercial sale in Europe is targeted for the fourth quarter of 2026, starting with Germany. Reports of the presentation say that sale would trigger a US$35 million milestone, with further sales milestones available, and that royalty rates in Europe and Japan start at 10% on annual net sales up to US$250 million and rise in higher tiers. Those terms should be confirmed against the primary announcements.

A Phase 3 study of trofinetide in Japan is also expected to report top-line results in the fourth quarter of 2026, with a Japanese filing planned for 2027.

Management has said it expects to give timing guidance for results once about half of participants are enrolled. The FDA has granted Orphan Drug, Rare Pediatric Disease and Fast Track designations. If approved, a rare paediatric disease priority review voucher could be valuable, though that depends on rules and approvals not yet achieved.

Competitive position and sector conditions

Rare neurological disease drugs benefit from small patient groups, regulatory incentives and few competitors. Neuren's position rests on trofinetide being the only approved Rett syndrome therapy, and on its Partnership with a commercial-stage company.

That also concentrates risk. Gene therapies and other approaches to Rett syndrome are being researched, and any credible rival would change the outlook. DAYBUE's growth also depends on patient uptake, tolerability, reimbursement decisions in new countries and the new powder formulation, DAYBUE STIX.

Risks and what to watch

• Single-product dependence: royalties depend on one drug sold by a partner.

• Clinical risk: Phase 3 trials can fail, be delayed or cost more than planned.

• Regulatory and pricing risk in Europe and Japan.

• Currency: royalties are earned in US dollars but reported in Australian dollars.

• Dividend variability, since payouts follow income and research spending.

• Patent life and competition over the longer term.

Upcoming events include Germany's launch, the associated milestone payment, Japan Phase 3 results, a Pitt Hopkins syndrome FDA meeting, Neuren's own update on royalties, and enrolment progress in the Koala study. Each will help show whether the royalty base is broadening as intended. Investors may also want to read the full ASX announcements rather than relying on summaries, because milestone terms, guidance ranges and trial timetables can change between updates and are sometimes reported inconsistently by third parties.